Submitted by endpointsnews6292 in business
Illumina must pay a €432 million ($476 million) fine for buying the cancer-testing firm Grail without regulatory approval, the European Commission said today. The San Diego-based company closed the deal in 2021 despite the EU’s ongoing antitrust investigation…